论文部分内容阅读
目的:探讨与研究急性心肌梗死临床治疗效果和价值。方法:将我院收治急性心肌梗死患者共156例纳入研究并随机分为观察组和对照组,对照组给予临床常规加低分子肝素治疗,观察组在常规治疗+低分子肝素治疗基础上使用尿激酶溶栓治疗,观察并比较两组患者临床治疗效果,治疗后左心射血分数(LVEF)、室舒张末期内径(LVEDD)及并发症发生情况。结果:观察组临床疗效及LVEF、LVEDD水平均明显高于对照组,差别均具有统计学意义(P<0.05);并发症发生情况观察组明显低于对照组,P<0.05。结论:临床急性心肌梗死患者治疗中,在常规治疗及低分子肝素治疗的基础上使用尿激酶溶栓治疗,具有较高的临床治疗效果,值得临床积极推广使用。
Objective: To investigate and study the clinical effect and value of acute myocardial infarction. Methods: A total of 156 patients admitted to our hospital with acute myocardial infarction were included in the study and were randomly divided into observation group and control group. The control group was given routine clinical treatment plus low molecular weight heparin. The observation group was given routine treatment plus low molecular weight heparin Keto thrombolytic therapy was used to observe and compare the clinical curative effect, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and the incidence of complications after treatment. Results: The clinical curative effect and the levels of LVEF and LVEDD in the observation group were significantly higher than those in the control group (P <0.05). The incidence of complications in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Urokinase thrombolytic therapy based on routine treatment and low molecular weight heparin therapy in clinical AMI patients has high clinical effect and is worthy of clinical promotion.